Physician profile
Melissa Moody
NPI 1750505384
$1,206,442.87
in general payments reported to CMS, 2019-2025
37 companies · $293K in 2025
The $293K reported for 2025 was more than what 99% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $56K · 2020: $43K · 2021: $121K · 2022: $202K · 2023: $263K · 2024: $229K · 2025: $293K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $587K · Travel and Lodging: $87K · Consulting Fee: $78K · Honoraria: $18K · Food and Beverage: $16K · Education: $71.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $586,542.99 |
| Travel and Lodging | $86,616.41 |
| Consulting Fee | $77,749.25 |
| Honoraria | $18,425.00 |
| Food and Beverage | $15,610.36 |
| Education | $71.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $551,093.27 | 2019-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $329,241.09 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Abbvie INC. | $166,367.68 | 2021-2025 | |
| Axsome Therapeutics, INC. | $68,106.59 | 2022-2025 | Auvelity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $65,904.60 | 2021-2025 | Caplyta |
| Allergan, INC. | $14,571.73 | 2019-2020 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $8,260.95 | 2019-2023 | Rexulti |
| Janssen Pharmaceuticals, INC | $398.71 | 2019-2025 | Spravato, Invega Trinza, Invega Sustenna |
| Alkermes, INC. | $391.04 | 2023-2025 | Aristada, Lybalvi, Vivitrol |
| E.R. Squibb & Sons, L.L.C. | $280.14 | 2025 | Cobenfy |
| Teva Pharmaceuticals USA, INC. | $271.48 | 2019-2025 | Austedo Xr, Austedo Xr |
| Lundbeck LLC | $265.65 | 2019-2025 | Rexulti, Vyepti |
| Vanda Pharmaceuticals INC. | $203.72 | 2021-2025 | Fanapt |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $127.47 | 2021-2024 | Lifevest |
| Takeda Pharmaceuticals U.S.A., INC. | $116.90 | 2019-2023 | Trintellix |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $90.50 | 2020-2023 | Yupelri |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $75.75 | 2020-2022 | |
| Novo Nordisk INC | $74.90 | 2020-2022 | |
| Amarin Pharma, INC. | $72.39 | 2020-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $71.92 | 2021-2023 | |
| Glaxosmithkline, LLC. | $68.27 | 2020-2021 | |
| Sunovion Pharmaceuticals INC. | $63.58 | 2019 | |
| Ironshore Pharmaceuticals INC. | $37.45 | 2022-2024 | |
| Collegium Pharmaceutical, INC. | $35.80 | 2025 | Jornay Pm |
| Amgen INC. | $29.49 | 2020-2021 | |
| Almatica Pharma LLC | $28.54 | 2021 | |
| Esperion Therapeutics, INC. | $25.63 | 2020-2021 | |
| Eisai INC. | $25.43 | 2020 | |
| Dexcom, INC. | $23.02 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.86 | 2021 | |
| Averitas Pharma INC. | $16.86 | 2024 | Qutenza |
| Indivior INC. | $16.82 | 2024 | Perseris |
| Exact Sciences Corporation | $15.93 | 2023 | Cologuard Collection Kit |
| Shire North American Group INC | $15.56 | 2019 | |
| Idorsia Pharmaceuticals US INC | $15.15 | 2023 | Quviviq |
| Avanir Pharmaceuticals, INC. | $12.27 | 2021 | |
| Ambu INC. | $9.73 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Moody listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.